text: <unk>  is an alkylating drug that is FDA approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.   Common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache (≥20%).
option_0: Trabectedin
option_1: Temoporfin
option_2: Verteporfin
option_3: Dalcetrapib
option_4: Vicriviroc
option_5: Diprenorfin
option_6: Niraparib
option_7: Etravirine